|
AL5300
|
DB04089 |
|
|
2',4'-Dinitrophenyl-2deoxy-2-Fluro-B-D-Cellobioside
|
DB04086 |
|
|
Open Form of 2'-Deoxy-Ribofuranose-5'-Phosphate
|
DB04087 |
|
|
2-deoxy-2-fluoro-α-D-mannose
|
DB04084 |
|
|
1-[Pyrrol-1-Yl-2,5-Dione-Methoxymethyl]-Pyrrole-2,5-Dione
|
DB04085 |
|
|
Decyloxy-Methanol
|
DB04082 |
|
|
N'-Pyridoxyl-Lysine-5'-Monophosphate
|
DB04083 |
|
|
RU78191
|
DB04080 |
|
|
(4s-Trans)-4-(Methylamino)-5,6-Dihydro-6-Methyl-4h-Thieno(2,3-B)Thiopyran-2-Sulfonamide-7,7-Dioxide
|
DB04081 |
|
|
AE-941
|
DB05387 |
[AE-941 is a naturally occurring anti-angiogenic compound, extracted from cartilage, with multiple anti-angiogenic mechanisms of action that provide broad therapeutic potential for a number of diseases. It is currently in international Phase III trials for renal cell carcinoma and non-small-cell lung cancer.] |
|
2,3-Dicarboxy-4-(2-Chloro-Phenyl)-1-Ethyl-5-Isopropoxycarbonyl-6-Methyl-Pyridinium
|
DB04055 |
|
|
Regramostim
|
DB05386 |
[Regramostim (GM-CSF) is a differentially glycosylated factor produced mainly by activated T cells and macrophages. Endothelial cells and fibroblasts can also produce GM-CSF after exposure to TNF-α, IL-1, IL-2 and IFN-γ. GM-CSF is found associated with extracellular matrix and in membrane-bound formats too. GM-CSF stimulates proliferation, activation and differentiation of macrophages and granulocytes and their progenitors.] |
|
PRO 2000
|
DB05385 |
[PRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It is being studied for the prevention of HIV infection and other sexually transmitted diseases. This medicine does not cure HIV infection or AIDS and is being studied to reduce the risk of passing the virus to other people.] |
|
Hypophosphite
|
DB04053 |
|
|
9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
|
DB04054 |
|
|
Carbopol 974P
|
DB05384 |
[Carbopol 974P is a highly carboxylated polymer composed of lightly cross-linked polyacrylic acid with a broad-spectrum mechanism based on acidification of pathogens. It was under development by ReProtect LLC. It is a gel that may help both block the spread of sexually transmitted diseases and reduce unwanted pregnancies. The compound, known as BufferGel, was in advanced clinical trials for its ability to prevent pregnancy, but was discontinued.] |
|
Pimagedine
|
DB05383 |
[Pimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease. It is an advanced glycation end product inhibitor which manages diabetic nephropathy, either alone or in combination with other therapies. It is beneficial in treating patients with diabetic nephropathy.] |
|
5-Phenylvaleric Acid
|
DB04051 |
|
|
3,4-Dimethylphenol
|
DB04052 |
|
|
Iodine
|
DB05382 |
[Molecualar iodine has been developed by Symbollon Pharmaceuticals. It is a potential treatment for moderate to severe cyclic pain and tenderness (clinical mastalgia) associated with fibrocystic breast disease (FBD).] |
